title: Mab labelled liposomes as selective vehicles for drugs in H.I.V. infected cells.
abstract: Being able to carry zidovudine (AZT) at known concentrations into CD4+/CD38+ and CD14+ cells permits:  - to reduce the drug dosage and to increase the interval for administration (until 1 dose I.V. every week);   - to modulate the drug concentration into the CD4+/CD38 an CD14+ cells in relation to the "in vitro" determined HIV sensitiveness;   - to eliminate haematological, medullary and general toxicity;   - to be able to treat severely hill patients.   Further studies are necessary in order to:  - To find out the better phase to start the therapy;   - To use several drugs with different mechanisms of action in order to slow down as much as possible the presence of resistant viral strains.   - As for other drugs which are beginning to be used with artificial vehicles, futher studies are required to improve the selectivity and safety of LIPOAZT for the target cells including macrophages.
authors.affiliation: Ist. Radiot. Univ. CAGLIARI, Cagliari, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Rombi
authors.forename: G
authors.initials: G
authors.lastname: Piu
authors.forename: S
authors.initials: S
authors.lastname: Piro
authors.forename: V
authors.initials: V
authors.lastname: Anedda